NASDAQ:XOMA XOMA (XOMA) Stock Forecast, Price & News $14.69 +0.01 (+0.07%) (As of 11:37 AM ET) Add Compare Share Share Today's Range$14.50▼$14.9650-Day Range$14.02▼$17.7152-Week Range$13.68▼$26.00Volume2,672 shsAverage Volume34,866 shsMarket Capitalization$168.49 millionP/E RatioN/ADividend YieldN/APrice Target$74.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability XOMA MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside403.7% Upside$74.00 Price TargetShort InterestBearish5.88% of Shares Sold ShortDividend StrengthN/ASustainability-0.22Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.50) to ($0.56) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.69 out of 5 starsMedical Sector825th out of 961 stocksPharmaceutical Preparations Industry395th out of 454 stocks 3.5 Analyst's Opinion Consensus RatingXOMA has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $74.00, XOMA has a forecasted upside of 403.7% from its current price of $14.69.Amount of Analyst CoverageXOMA has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted5.88% of the outstanding shares of XOMA have been sold short.Short Interest Ratio / Days to CoverXOMA has a short interest ratio ("days to cover") of 16.4, which indicates bearish sentiment.Change versus previous monthShort interest in XOMA has recently increased by 8.63%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldXOMA does not currently pay a dividend.Dividend GrowthXOMA does not have a long track record of dividend growth. Previous Next 3.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreXOMA has received a 26.63% net impact score from Upright. The largest positive contribution comes from its "Distributing knowledge" impact, which is false driven by its "Mutual funds investing in the pharmaceuticals industry" product. See details.Environmental SustainabilityThe Environmental Impact score for XOMA is -0.22. Previous Next 0.6 News and Social Media Coverage MarketBeat Follows2 people have added XOMA to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, XOMA insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.20% of the stock of XOMA is held by insiders.Percentage Held by Institutions65.35% of the stock of XOMA is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for XOMA are expected to grow in the coming year, from ($2.50) to ($0.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of XOMA is -5.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of XOMA is -5.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXOMA has a P/B Ratio of 1.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About XOMA (NASDAQ:XOMA) StockXOMA Corporation operates as a biotech royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with various assets. The company was incorporated in 1981 and is headquartered in Emeryville, California.Read More XOMA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XOMA Stock News HeadlinesSeptember 13, 2023 | nasdaq.comHC Wainwright & Co. Reiterates XOMA (XOMA) Buy RecommendationSeptember 6, 2023 | finance.yahoo.comXOMA to Present at H.C. Wainwright 25th Annual Global Investment ConferenceSeptember 26, 2023 | Micro-Cap Stock Trader (Ad)U.S. drive to onshore battery supply chains could create big winners in lithiumInvestor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsAugust 31, 2023 | msn.comXOMA (XOMA) Price Target Increased by 18.40% to 75.48August 9, 2023 | msn.comHC Wainwright & Co. Maintains XOMA (XOMA) Buy RecommendationAugust 8, 2023 | finanznachrichten.deXOMA Corporation: XOMA Reports Second Quarter 2023 Financial Results and Provides Update on its Royalty Monetization StrategyAugust 8, 2023 | msn.comXOMA GAAP EPS of -$0.59, revenue of $1.7MJuly 7, 2023 | finanznachrichten.deSimple Spirits Company LLC: Simple Spirits Shines at the San Francisco World Spirits CompetitionSeptember 26, 2023 | Micro-Cap Stock Trader (Ad)U.S. drive to onshore battery supply chains could create big winners in lithiumInvestor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsJune 28, 2023 | benzinga.comTom Burns Elected to the Acorda Therapeutics Board of DirectorsJune 22, 2023 | msn.comArimoclomol and Aldoxorubicin Acquisition to Bolster XOMA's Revenue Growth: AnalystJune 22, 2023 | seekingalpha.comXOMA acquires drug rights from LadRx for $5MJune 22, 2023 | finance.yahoo.comLadRx Completes Non-Dilutive Financing Transaction for up to $11 Million with XOMA CorporationJune 22, 2023 | finance.yahoo.comXOMA Acquires Royalty and Milestone Economics to Phase 3 First-In-Class Orphan Disease Asset for Niemann-Pick Disease Type C (NPC) and Phase 2 Oncology AssetJune 15, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Xoma (XOMA)June 15, 2023 | benzinga.comHC Wainwright & Co. Reiterates Buy on XOMA, Maintains $69 Price TargetMay 24, 2023 | msn.comXOMA's Return On Capital Employed InsightsMay 23, 2023 | seekingalpha.comXOMAP XOMA Corporation 8.625% CUM PERP PFD SER AMay 16, 2023 | finance.yahoo.comShareholders in XOMA (NASDAQ:XOMA) are in the red if they invested five years agoMay 11, 2023 | finance.yahoo.comAcorda Therapeutics Reports First Quarter 2023 Financial ResultsMay 10, 2023 | msn.comXOMA: Q1 Earnings InsightsMay 10, 2023 | msn.comXOMA GAAP EPS of -$0.98, revenue of $0.44MMay 9, 2023 | finance.yahoo.comXOMA Reports First Quarter 2023 Financial Results and Provides Update on the Acceleration of its Differentiated Royalty Monetization StrategyApril 26, 2023 | finance.yahoo.comXOMA to Present at H.C. Wainwright BioConnect Investor ConferenceMarch 30, 2023 | finance.yahoo.comXOMA Acquires Cashflow-Generating Asset for its Royalty and Milestone PortfolioMarch 10, 2023 | finance.yahoo.comXOMA Full Year 2022 Earnings: Revenues Beat Expectations, EPS In LineMarch 9, 2023 | finance.yahoo.comXOMA Reports Full-Year 2022 Financial Results and Provides Update to the Acceleration of its Differentiated Royalty Monetization StrategySee More Headlines Receive XOMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter. Email Address XOMA Company Calendar Last Earnings8/08/2023Today9/26/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:XOMA CUSIP98419J10 CIK791908 Webwww.xoma.com Phone(510) 204-7200Fax510-649-7571Employees11Year Founded1981Price Target and Rating Average Stock Price Forecast$74.00 High Stock Price Forecast$74.00 Low Stock Price Forecast$74.00 Forecasted Upside/Downside+403.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,100,000.00 Net Margins-663.07% Pretax Margin-629.51% Return on Equity-22.33% Return on Assets-19.59% Debt Debt-to-Equity RatioN/A Current Ratio5.42 Quick Ratio5.42 Sales & Book Value Annual Sales$6.03 million Price / Sales27.94 Cash FlowN/A Price / Cash FlowN/A Book Value$10.83 per share Price / Book1.36Miscellaneous Outstanding Shares11,470,000Free Float10,876,000Market Cap$168.49 million OptionableNot Optionable Beta0.87 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Thomas M. Burns (Age 49)Sr. VP of Fin. & CFO Comp: $538.45kMr. Owen P. Hughes Jr. (Age 48)Exec. Chairman & Interim CEO Mr. Brad SitkoChief Investment OfficerKey CompetitorsRigel PharmaceuticalsNASDAQ:RIGLEmergent BioSolutionsNYSE:EBSMerrimack PharmaceuticalsNASDAQ:MACKVerastemNASDAQ:VSTMVanda PharmaceuticalsNASDAQ:VNDAView All CompetitorsInsiders & InstitutionsBarclays PLCBought 1,468 shares on 9/21/2023Ownership: 0.013%California State Teachers Retirement SystemBought 2,432 shares on 8/21/2023Ownership: 0.021%Stonepine Capital Management LLCBought 31,303 shares on 8/16/2023Ownership: 3.045%Royal Bank of CanadaSold 1,776 shares on 8/15/2023Ownership: 0.038%Citadel Advisors LLCBought 1,600 shares on 8/15/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions XOMA Stock - Frequently Asked Questions Should I buy or sell XOMA stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for XOMA in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" XOMA shares. View XOMA analyst ratings or view top-rated stocks. What is XOMA's stock price forecast for 2023? 1 analysts have issued 1-year target prices for XOMA's shares. Their XOMA share price forecasts range from $74.00 to $74.00. On average, they expect the company's share price to reach $74.00 in the next year. This suggests a possible upside of 403.7% from the stock's current price. View analysts price targets for XOMA or view top-rated stocks among Wall Street analysts. How have XOMA shares performed in 2023? XOMA's stock was trading at $18.40 on January 1st, 2023. Since then, XOMA shares have decreased by 20.2% and is now trading at $14.69. View the best growth stocks for 2023 here. When is XOMA's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our XOMA earnings forecast. How were XOMA's earnings last quarter? XOMA Co. (NASDAQ:XOMA) announced its quarterly earnings data on Tuesday, August, 8th. The biotechnology company reported ($0.59) EPS for the quarter, missing analysts' consensus estimates of ($0.52) by $0.07. The biotechnology company had revenue of $1.66 million for the quarter, compared to analyst estimates of $1.70 million. XOMA had a negative net margin of 663.07% and a negative trailing twelve-month return on equity of 22.33%. What is John Varian's approval rating as XOMA's CEO? 11 employees have rated XOMA Chief Executive Officer John Varian on Glassdoor.com. John Varian has an approval rating of 73% among the company's employees. What other stocks do shareholders of XOMA own? Based on aggregate information from My MarketBeat watchlists, some companies that other XOMA investors own include Cytokinetics (CYTK), Alnylam Pharmaceuticals (ALNY), Ascent Solar Technologies (ASTI), CTI BioPharma (CTIC), OPKO Health (OPK), Uranium Energy (UEC), Gilead Sciences (GILD), NXP Semiconductors (NXPI) and Ekso Bionics (EKSO). What is XOMA's stock symbol? XOMA trades on the NASDAQ under the ticker symbol "XOMA." Who are XOMA's major shareholders? XOMA's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.74%), Stonepine Capital Management LLC (3.05%), Stonepine Capital Management LLC (3.05%), Geode Capital Management LLC (1.34%), State Street Corp (1.11%) and HighVista Strategies LLC (1.04%). Insiders that own company stock include Bradley Sitko, Bvf Partners L P/Il, James R Neal, James R Neal, Matthew D Perry, Owen Hughes and Thomas M Burns. View institutional ownership trends. How do I buy shares of XOMA? Shares of XOMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is XOMA's stock price today? One share of XOMA stock can currently be purchased for approximately $14.69. How much money does XOMA make? XOMA (NASDAQ:XOMA) has a market capitalization of $168.49 million and generates $6.03 million in revenue each year. The biotechnology company earns $-17,100,000.00 in net income (profit) each year or ($2.69) on an earnings per share basis. How can I contact XOMA? XOMA's mailing address is 2200 POWELL STREET SUITE 310, EMERYVILLE CA, 94608. The official website for the company is www.xoma.com. The biotechnology company can be reached via phone at (510) 204-7200, via email at jsnowden@oratoriumgroup.com, or via fax at 510-649-7571. This page (NASDAQ:XOMA) was last updated on 9/26/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XOMA Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.